Brain MRI atrophy quantification in MS
Autor: | Marco Battaglini, Elisabetta Pagani, Mark Jenkinson, Roland G. Henry, Ralph H.B. Benedict, Nicola De Stefano, Massimo Filippi, Jeroen J. G. Geurts, Maria A. Rocca, Mark A. Horsfield |
---|---|
Přispěvatelé: | Rocca, Ma, Battaglini, M, Benedict, Rh, De Stefano, N, Geurts, Jj, Henry, Rg, Horsfield, Ma, Jenkinson, M, Pagani, E, Filippi, Massimo |
Rok vydání: | 2016 |
Předmět: |
LARGE COHORT
Neurodegenerative 030218 nuclear medicine & medical imaging Computer-Assisted 0302 clinical medicine Brain mri LESION BURDEN Brain Magnetic Resonance Imaging medicine.anatomical_structure VOXEL-BASED MORPHOMETRY Neurological Brain size Biomedical Imaging Cognitive Sciences Cohort study medicine.medical_specialty Multiple Sclerosis Clinical Sciences Bioengineering Autoimmune Disease White matter 03 medical and health sciences VOLUME CHANGES Physical medicine and rehabilitation Atrophy Clinical Research Image Interpretation Computer-Assisted medicine CORTICAL ATROPHY Humans PROGRESSIVE MULTIPLE-SCLEROSIS Image Interpretation Neurology & Neurosurgery Views & Reviews business.industry DISABILITY Multiple sclerosis Neurosciences Voxel-based morphometry medicine.disease Brain Disorders GRAY-MATTER ATROPHY FOLLOW-UP RISK-FACTORS Clinical trial Neurology (clinical) business 030217 neurology & neurosurgery |
Zdroj: | Neurology, vol 88, iss 4 |
ISSN: | 1526-632X 0028-3878 |
Popis: | Patients with the main clinical phenotypes of multiple sclerosis (MS) manifest varying degrees of brain atrophy beyond that of normal aging. Assessment of atrophy helps to distinguish clinically and cognitively deteriorating patients and predicts those who will have a less-favorable clinical outcome over the long term. Atrophy can be measured from brain MRI scans, and many technological improvements have been made over the last few years. Several software tools, with differing requirements on technical ability and levels of operator intervention, are currently available and have already been applied in research or clinical trial settings. Despite this, the measurement of atrophy in routine clinical practice remains an unmet need. After a short summary of the pathologic substrates of brain atrophy in MS, this review attempts to guide the clinician towards a better understanding of the methods currently used for quantifying brain atrophy in this condition. Important physiologic factors that affect brain volume measures are also considered. Finally, the most recent research on brain atrophy in MS is summarized, including whole brain and various compartments thereof (i.e., white matter, gray matter, selected CNS structures). Current methods provide sufficient precision for cohort studies, but are not adequate for confidently assessing changes in individual patients over the scale of months or a few years. |
Databáze: | OpenAIRE |
Externí odkaz: |